Pharmacokinetics of high doses of cyanocobalamin administered by intravenous injection for 26 weeks in rats

Clinical and Experimental Pharmacology and Physiology

Volumn 32, Issue 1-2, 2005, Pages 13-18

  Nava Ocampo, Alejandro A ^a,c   Pastrak, Aleksandra ^b   Cruz, Tony ^b   Koren, Gideon ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b Transition Therapeutics   (Canada)

^c HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

Author keywords

Cobalamins; Maximum tolerated dose; Pharmacokinetics; Vitamin B12

Indexed keywords

CYANOCOBALAMIN;

ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; CHRONIC DRUG ADMINISTRATION; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MEGADOSE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CLEARANCE; KIDNEY TUBULE ABSORPTION; MALE; MAXIMUM TOLERATED DOSE; NEUROLOGIC DISEASE; NONCOMPARTMENT ANALYSIS; NONHUMAN; NONLINEAR SYSTEM; PHARMACOKINETICS; POPULATION; POPULATION PHARMACOKINETICS; RAT;

ALGORITHMS; ANIMALS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HEMATINICS; INJECTIONS, INTRAVENOUS; MALE; MODELS, STATISTICAL; RATS; RATS, SPRAGUE-DAWLEY; VITAMIN B 12;

EID: 14644402970     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2005.04145.x     Document Type: Article

References (12)

1. Watanabe T, Kaji R, Oka N, Bara W, Kimura J. Ultra-high dose methylcobalamin promotes nerve regeneration in experimental acrylamide neuropathy. J. Neurol. Sci. 1994; 122: 140-3.
2. Ide H, Fujiya S, Asanuma Y, Tsuji M, Sakai H, Agishi Y. Clinical usefulness of intrathecal injection of methylcobalamin in patients with diabetic neuropathy. Clin. Ther. 1987; 9: 183-92.
3. Kaji R, Kodama M, Imamura A et al. Effect of ultrahigh-dose methylcobalamin on compound muscle action potentials in amyotrophic lateral sclerosis: A double-blind controlled study. Muscle Nerve 1998; 21: 1775-8.
4. Kodama M, Kaji R, Kohara N et al. Double-blind crossover trial of ultra-high dose of methylcobalamine for amyotropic lateral sclerosis. Neurology 2001; 54 (Suppl. 3): S48.006 (Abstract).
5. Rabinoff M, inventor. Transition Therapeutics Inc. (Toronto, Canada), assignee. Use of methyl donor compounds to treat neurological dysfunction associated with immune defects. US patent no. 5716941. 2 October 1998.
6. 12a excretion. Fed. Proc. 1985; 44: Abstract 4149.
7. 12 and hepatitis C: Molecular mechanism and human pathology. Proc. Natl Acad. Sci. USA 2001; 98: 4916-21.
8. 12 on valproic acid-induced teratogenesis in mice. Fundam. Appl. Toxicol. 1992; 18: 389-94.
9. James J, Warin RP. Sensitivity to cyanocobalamin and hydroxocobalamin. BMJ 1971; 2: 262.
10. 12 appearing after several years of therapy. Age Ageing 1981; 10: 196-7.
11. Vaidyanathan S, Soni BM, Oo T, Watt JW, Sett P, Singh G. Syncope following intramuscular injection of hydroxocobalamin in a paraplegic patient: Indication for oral administration of cyanocobalamin in spinal cord injury patients. Spinal Cord 1999; 37: 147-9.
12. Vidal C, Lorenzo A. Anaphylactoid reaction to hydroxycobalamin with tolerance of cyanocobalamin. Postgrad. Med. J. 1998; 74: 702.